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INFECTION – Clinical Outcomes Studies
PIN1
HEPATITIC-C BURDEN ASSESSMENT IN FRANCE FROM A 
TRANSMISSION MODEL
Mehra M, DiBello J, Zhang H
Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA
OBJECTIVES: A HCV transmission model has been previously developed to describe 
the dynamics of chronic hepatitis-C (CHC) transmission and progression in the US. 
In this study, we adapted this model to assess the public health burden of HCV in 
France. METHODS: This mathematical model captures ﬂows across population com-
partments based on status of injection-drug use, CHC infection, diagnosis, genotypes, 
treatment/re-treatment, SVR and disease progression. All input values and predicted 
values of 2002–2006 from the calibrated model matched closely to published French 
data. The model was then applied to assess the potential beneﬁts of a hypothetical 
new CHC regimen (NEW) compared to the current pegylated-interferon/ribavirin 
(P/R) treatment. Key assumptions in the model included: NEW becomes available in 
2011 with 25% incremental SVR rate (70% vs. 45%) from P/R for genotype-1 
treatment-naïve patients; 50% SVR rate could be achieved by NEW to re-treat P/R 
treatment failure patients (TFs); TFs from NEW are not re-treated with NEW; NEW 
is not used to treat genotype 2/3 patients; P/R durations are consistent with current 
treatment guidelines by genotypes; diagnosis and treatment rates remain unchanged. 
RESULTS: Our model projects that, in contrast to P/R projections, the use of hypo-
thetical NEW could cure 32,885 more patients (as deﬁned by the achievement of SVR), 
and could prevent 7,883 more new cases of CHC, 20,658 more new cases of advanced 
liver diseases (ALD), and 11,100 more deaths. CHC prevalence in 2040 under NEW 
is also projected to be lower (29,757 fewer cases), mainly among TFs (16,782) and 
ALD patients (11,201). CONCLUSIONS: Our model suggests that a novel CHC 
regimen with higher SVR than the current P/R treatment could potentially have a 
substantial public health impact in France, mainly due to the associated decrease in 
the incidence of CHC prevalence, CHC-associated deaths, ALD patients and number 
of treatment failure patients.
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IMPACT OF SUSTAINED VIROLOGICAL RESPONSE (SVR) ON LIFE 
EXPECTANCY AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN 
CHRONIC HEPATITIS C (CHC) PATIENTS
Cure S1, Bianic F1, Dartois L1, Cawston H1, Zhang H2
1i3 Innovus, Uxbridge, Middlesex, UK, 2Johnson & Johnson Pharmaceutical Services LLC, 
Raritan, NJ, USA
OBJECTIVES: CHC treatment has been evaluated for its efﬁcacy (SVR) and long-term 
effects in terms of reducing disease progression to advanced stages, long-term improve-
ment on quality of life, and reduction of health care costs. The objective is to assess 
the impact of SVR in CHC patients on lifetime life years (LY) and QALY based on 
published cost-utility analyses. METHODS: A systematic literature review identiﬁed 
publications reporting the cost-effectiveness of antiviral therapies in CHC (November 
2009). PubMed, the Centre for Reviews and Dissemination and health technology 
assessment (HTA) reports were searched. We included all cost-effectiveness studies 
based on a Markov model reporting lifetime LYs and QALYs. All of these published 
studies assumed that patients in the comparison groups have the same attributes such 
as starting age, disease states, disease progression probabilities, mortality, and utilities 
associated with each health state, etc. We did a back calculation on the LYs and 
QALYs associated with SVR and non-SVR because that SVR difference is the only 
difference between the two comparators for the lifetime QALY and LY differences in 
the ﬁnal reported incremental cost-effectiveness ratio (ICER) results. RESULTS: A 
total of 893 unique references were retrieved and 80 articles met the inclusion criteria. 
Among them, 46 reported for each comparator the SVR rate, LYs and QALYs. 
Compared to non-SVR status, SVR was consistently associated with more LYs (24.5 
ranging from 15.9 to 36.5 vs. 21.2 ranging from 14.2 to 32.7) and QALYs (19.2 
ranging from 10.1 to 45.0 vs. 15.4 ranging from 9.9 to 30.7). This trend was consistent 
across all studies where this analysis is feasible (N = 40). CONCLUSIONS: In this 
literature review, SVR is associated with longer life expectancy and QALYs than non-
SVR. It is important to account for these lifetime beneﬁts when the values of an 
antiviral treatment in CHC are being evaluated.
INFECTION – Cost Studies
PIN5
A BUDGET IMPACT ANALYSIS OF THREE PRESURGICAL SKIN 
ANTISEPSIS PROTOCOLS
Zhou S1, Carlson A2
1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden 
Prairie, MN, USA
OBJECTIVES: Surgical site infections (SSIs) occur in up to 11.6% of surgeries, length-
ening hospital stays and incurring additional costs. Presurgical antiseptic techniques 
vary in the rates of SSIs and their impact on a hospital or surgical center’s budget. 
The purpose of this study was to estimate the net budget impact of three antisepsis 
techniques. METHODS: A budget impact analysis using ISPOR guidelines was com-
pleted. Costs associated with DuraPrep, ChloraPrep, and Povidone-Iodine scrub-paint 
(PI) were obtained from current market sources. Rates of SSIs were derived from 
published clinical studies. Incremental costs to treat SSIs were derived from literature 
and adjusted to current U.S. dollars using the medical component of the Consumer 
Price Index. Presurgical skin preparation time estimates were obtained from product 
literature and costs calculated based on per minute surgical suite charges. Total cost 
per 100 surgeries was calculated: [antisepsis cost + costs of presurgical preparation + 
Incremental costs to treat SSIs (SSI rate X 100 X average cost to treat SSI)]. Estimates 
were prepared in an interactive spreadsheet to modify cost parameters and rates of 
SSIs. RESULTS: PI had the lowest product cost but its skin preparation protocol took 
5 times longer than DuraPrep or ChloraPrep, resulting in large presurgical expendi-
tures. ChloraPrep was 1.7 times more expensive than DuraPrep per unit but took 
similar time to apply. DuraPrep provided total cost savings relative to Chloraprep and 
PI. The total costs per 100 surgeries using DuraPrep, ChloraPrep, and PI were 
$166,920, $274,508, and $216,500 respectively. The cost savings differences were 
due to: 1) reduced preparation time (DuraPrep: 3 mins, ChloraPrep: 3 mins, PI: 
13 mins); 2) lower SSIs (DuraPrep: 4.8%, ChloraPrep: 8.2%, PI: 4.8%); and 3) per 
unit product cost difference (DuraPrep: $4.27, ChloraPrep: $7.08, PI: $0.07). CON-
CLUSIONS: Based on 100 surgeries, DuraPrep provides both time and cost savings 
relative to PI and ChloraPrep.
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COST-ANALYSIS OF LEVOFLOXACIN IV COMPARED TO OTHER 
GUIDELINE-ENDORSED THERAPIES FOR PATIENTS HOSPITALIZED 
WITH COMMUNITY-ACQUIRED PNEUMONIA
Kongnakorn T1, Mody S2, Li Q1, Frei C3, Raut M4, Schein J4
1United BioSource Corporation, Lexington, MA, USA, 2Ortho-McNeil Janssen Scientiﬁc 
Affairs, Chapel Hill, NC, USA, 3University of Texas, Austin, San Antonio, TX, USA, 
4Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: Levoﬂoxacin IV (LEV) has been shown to reduce hospital length of 
stay (LOS) in patients hospitalized with community-acquired pneumonia (CAP) com-
pared to other IDSA/ATS guideline recommended antibiotic regimens. This study 
aimed at estimating the budgetary impact of utilizing LEV in a hospital formulary for 
treatment of CAP in the United States. METHODS: An Excel®-based model was 
developed in accordance with Good Research Practices for Budget Impact Analysis 
disseminated by ISPOR to estimate the budget impact of increasing the use of or 
adding LEV in a hospital formulary. The model was based on published data on 
shorter LOS associated with LEV compared to moxiﬂoxacin IV (MOX) or ceftriaxone 
and azithromycin combination therapy (0.54 and 0.8 days, respectively). Model inputs 
included annual hospital admission for CAP; current proportional share of LEV, 
MOX, combination therapy, and other antibiotic regimens (30%, 30%, 30%, and 
10%, respectively); antibiotic drug costs (wholesale acquisition costs); average LOS 
and hospital costs from MedPAR. All costs were in 2007 USD. A new proportional 
share of 60% LEV, 15% MOX, 15% combination therapy, and 10% other regimens 
was assumed for this analysis. Sensitivity analysis explored the impact on results of 
different proportions of LEV use. RESULTS: The total cost per treated patient with 
the current proportional share was estimated to be $6900. With the new share 
(increasing LEV utilization from 30% to 60%), total cost was estimated to decrease 
to $6630. A 3.9% ($270) reduction in hospital budget was mainly due to shorter LOS 
associated with LEV. Savings in pharmacy costs were 13% ($35/patient). Hospitals 
that switched all MOX and combination therapy utilization to LEV, yielded cost 
savings of $540/patient. CONCLUSIONS: The model predicts that in the base case 
scenario an increase in LEV for CAP inpatient treatment would yield savings to the 
hospital’s total and pharmacy budgets.
PIN9
COST-OF-ILLNESS OF CHRONIC HEPATITIS B INFECTION IN VIETNAM
Tu HAT
University of Groningen, Groningen, Groningen, The Netherlands
OBJECTIVES: Vietnam is a high endemic country of hepatitis B virus infection, the 
most common cause of liver diseases. Our study aimed to assess the total cost of 
treatment chronic hepatitis B (CHB) infection and its complications in a cost-of-illness 
analysis to quantify the economic burden of CHB infections in Vietnam. METHODS: 
Micro-costing approach was applied. Direct medical cost, direct non-medical and 
indirect costs incurred due to chronic hepatitis B-related disease stages to both inpa-
tients and outpatients were collected and estimated for the year 2008. One-and 
two-way sensitivity analyses were performed on the cost calculated. RESULTS: In 
2008, the total cost of CHB infection and its complications was estimated to be around 
US$ 10 billion (or US$ 9 billion contributable to the direct medical cost). Antivirals 
are still very expensive in Vietnam in comparison to other countries and the major 
driver of costly treatment of CHB infection in the country. If all Vietnamese patients 
received treatment of CHB infections, the estimated treatment cost would be twice as 
much as the total health budget of Vietnam. This highlighted the possibilities that a 
signiﬁcant proportion of CHB infections in Vietnam are not being treated; the patients 
are bearing the extra cost out-of-pocket, or they are seeking treatment from traditional 
medicines. CONCLUSIONS: Treatment of CHB infection is very expensive and 
becomes a medical problem and a social issue. Given the GDP per capita of around 
$ 1024, it is potentially catastrophic for those affected. It is urgent that Vietnam should 
consider universal HBV vaccination of both newborns and adolescents. It should re-
examine its pharmaceutical policy to ensure the cost of antivirals to be affordable to 
patients. Necessary steps should be taken to ensure that the health system has mecha-
nisms in place to ensure ﬁnancial protection to affected patients and in need of 
treatment.
